MAPSYNE · Miniaturized automated patch-clamp system combined with high-density microelectrode arrays for multi-scale functional mapping of neuronal networks
„Хоризонт 2020“ — Действия „Мария Склодовска-Кюри“
- Период
- 2018-12-01 → 2020-11-30
- Финансиране от ЕС
- 187 420 €
- Участници
- 1
- Схема
- MSCA-IF-EF-SE
Линиите свързват координатора с партньорите.
Накратко на български
Автоматизирана система за измерване на електрическата активност в невронни мрежи ще анализира работата на синапсите при болести като Алцхаймер и Паркинсон. Това ще помогне за разработването на нови методи за тестване на лекарства срещу заболявания на централната нервна система.
Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.
Резултати накратко
Miniaturized automated patch-clamp system combined with high-density microelectrode arrays for multi-scale functional mapping of neuronal networks
More than one billion people worldwide (165 million in Europe) suffer from diseases of the central nervous system (CNS). With Europe's aging societies, the European Commission identified brain research as one of the key research areas under healthcare. Many neurodegenerative diseases are still without cure (e.g., Parkinson’s, amyotrophic lateral sclerosis (ALS) and Alzheimer’s) and repeated failures in clinical trials increase the demand for novel screening technologies to be implemented in the early phases of drug discovery. Recent studies show that synaptic dysfunction is involved in CNS diseases. New technologies for neuronal screening targeting synaptic and network activity, combined with disease model cells in vitro, will enable novel functional assays for CNS drug discovery. MAPSYNE project objective is to develop a miniaturized automated patch-clamp system combined with high-density microelectrode arrays (HD-MEAs) for multi-scale functional mapping of neuronal networks.
Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз
Цел на проекта
More than one billion people worldwide (165 million in Europe) suffer from diseases of the central nervous system (CNS). With Europe's aging societies, the European Commission identified brain research as one of the key research areas under healthcare (https://ec.europa.eu/research/health/). Many neurodegenerative diseases are still without cure (e.g., Parkinson’s, amyotrophic lateral sclerosis (ALS) and Alzheimer’s) and repeated failures in clinical trials increase the demand for novel screening technologies to be implemented in the early phases of drug discovery.Recent studies show that synaptic dysfunction is involved in CNS diseases. New technologies for neuronal screening targeting synaptic and network activity, combined with disease model cells in vitro, will enable novel functional assays for CNS drug discovery. This project aims to develop MAPSYNE, a Miniaturized Automated Patch-clamp SYstem combined with high-density microelectrode arrays (HD-MEAs) for multi-scale functional mapping of NEuronal networks. Patch-clamp allows detection of synaptic events and action potentials (APs) of single cells, while HD-MEAs record APs of thousands of neurons in parallel (also track APs propagating along axons). Combining the two methods will allow access to neuronal electrical signals across spatial and temporal scales.MAPSYNE's main objectives are (1) the development of hardware and software for a fully automated mini-patching system on HD-MEAs and (2) proof-of-concept experiments using primary and human induced pluripotent stem cell (h-iPSC)-derived neuronal networks.MAPSYNE will be designed for long-term, label-free recording of cell cultures. Other applications include local application of drugs (e.g, synaptic blockers on neuronal compartments). After this project, the ER envisions the commercialization of MAPSYNE, and eventually, its usage for preclinical CNS drug discovery.
Оригинален текст от CORDIS (на английски).
Участници
- MAXWELL BIOSYSTEMS AG · ZURICHКоординаторШвейцария
Връзки
Данни: CORDIS, © Европейски съюз